EU Supplementary Protection Certificate Mechanism Needs To Go, Say Campaigners
Executive Summary
A group of more than 30 NGOs has urged the European Commission to consider abolishing the system of granting supplementary protection certificates to pharmaceutical companies, saying it delays generic competition and affects the availability of affordable medicines. A UK-based patent attorney, however, says the assertions made by the NGOs are not supported by the evidence.
You may also be interested in...
Consultation To Help Determine Whether EU SPC Framework Fit For Purpose
The European Commission has launched a consultation on proposals to “recalibrate” supplementary protection certificates and patent research exemptions.
Consultation To Help Determine Whether EU SPC Framework Fit For Purpose
The European Commission has launched a consultation on proposals to “recalibrate” supplementary protection certificates and patent research exemptions.
France In Talks With BeNeLuxA Access To Meds Coalition; Group Plans Expansion Beyond EU
The BeNeLuxA collaboration for sustainable access to medicines may soon expand further. Future partners could include France and non-EU markets.